- Home
- EQS vs CING Comparison
EQS vs CING Comparison
Compare EQS & CING Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EQS
- CING
- Stock Information
- Founded
- EQS 1991
- CING 2012
- Country
- EQS United States
- CING United States
- Employees
- EQS N/A
- CING N/A
- Industry
- EQS Finance Companies
- CING Biotechnology: Pharmaceutical Preparations
- Sector
- EQS Finance
- CING Health Care
- Exchange
- EQS Nasdaq
- CING Nasdaq
- Market Cap
- EQS 13.9M
- CING 13.1M
- IPO Year
- EQS N/A
- CING 2021
- Fundamental
- Price
- EQS $1.00
- CING $4.25
- Analyst Decision
- EQS
- CING Strong Buy
- Analyst Count
- EQS 0
- CING 4
- Target Price
- EQS N/A
- CING $30.67
- AVG Volume (30 Days)
- EQS 4.5K
- CING 97.0K
- Earning Date
- EQS 01-01-0001
- CING 05-07-2025
- Dividend Yield
- EQS N/A
- CING N/A
- EPS Growth
- EQS N/A
- CING N/A
- EPS
- EQS N/A
- CING N/A
- Revenue
- EQS $1,274,000.00
- CING N/A
- Revenue This Year
- EQS N/A
- CING N/A
- Revenue Next Year
- EQS N/A
- CING N/A
- P/E Ratio
- EQS N/A
- CING N/A
- Revenue Growth
- EQS 411.65
- CING N/A
- 52 Week Low
- EQS $0.87
- CING $1.80
- 52 Week High
- EQS $1.53
- CING $20.83
- Technical
- Relative Strength Index (RSI)
- EQS 45.90
- CING 56.43
- Support Level
- EQS $0.93
- CING $4.03
- Resistance Level
- EQS $1.06
- CING $4.61
- Average True Range (ATR)
- EQS 0.05
- CING 0.31
- MACD
- EQS 0.01
- CING 0.04
- Stochastic Oscillator
- EQS 68.42
- CING 70.25
About EQS Equus Total Return Inc.
Equus Total Return Inc is a United States-based closed-end management investment company. It invest primarily in companies pursuing growth either through acquisition or organically, leveraged buyouts, management buyouts and recapitalizations of existing businesses or special situations and achieve capital appreciation by making investments in equity and equity-oriented securities issued by privately-owned companies or smaller public companies in transactions.
About CING Cingulate Inc.
Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.